Document:

EX-10.4

 Exhibit 10.4 

ROFN AGREEMENT 

THIS AGREEMENT (this “Agreement”) is effective as of March 31, 2014 (the “Effective Date”), by and
between rEVO Biologics, Inc., a Massachusetts corporation, having its principal place of business located at 175 Crossing Boulevard, Framingham, Massachusetts, 01702 (“rEVO”) and Laboratoire français du Fractionnement et des
Biotechnologies, a French Corporation, having its principal place of business located at 3 avenue des Tropiques - ZA de Courtaboeuf, 91940 (“LFB” and together with rEVO the “Parties” and each a
“Party”). 
 W I T N E S S E T H : 

WHEREAS, rEVO desires to obtain, and LFB desire to grant to rEVO, rights of first negotiation for commercialization of Fibrinogen and
Wilfactin in the United States of America on the terms set forth herein. 
 NOW, THEREFORE, subject to the terms, conditions, covenants and
provisions of this Agreement, rEVO and LFB each mutually covenant and agree as follows: 
 1. DEFINITIONS 

(a) “Affiliate” means any corporation or other entity that is directly or indirectly controlling, controlled by or under the
common control with a Party hereto. For the purpose of this Agreement, “control” includes the direct or indirect ownership of at least fifty percent (50%) of the outstanding shares or other voting rights of the subject entity to elect
directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority. 
 (b)
“Fibrinogen” means a human plasma-derived factor I concentrate and indicated for treatment and prophylaxis of bleeding in patients with congenital hypo-, dys- or afibrinogenaemia with bleeding tendency and as complementary therapy
to management of uncontrolled severe hemorrhage in situations of acquired hypofibrinogenemia commercialized as of the Effective Date by LFB. 

(c) “ROFN Products” means and includes Fibrinogen and Wilfactin and each is a “ROFN Product.” 

(d) “Third Party” means any person or entity other than the Parties and their Affiliates. 

(e) “Wilfactin” means a human plasma-derived von Willebrand factor concentrate and indicated for the control and prevention
of bleeding or in elective surgical or invasive procedure settings in severe von Willebrand disease (VWD) as well as mild to moderate VWD where use of desmopressin (DDAVP) treatment alone is known or suspected to be ineffective or contraindicated
commercialized as of the Effective Date by LFB. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 2
 
  

 2. ROFN FOR US DISTRIBUTION RIGHTS 

(a) Grant of ROFN. LFB hereby grants to rEVO exclusive rights of first negotiation to obtain the exclusive right to market and
distribute each of the ROFN Products for all indications in United States as set forth herein. If and when LFB desires to entrust to a Third Party rights to commercialize a ROFN Product in United States, LFB shall first so notify rEVO of the such
decision. Upon receipt of such notice, rEVO shall have a period of [***] to notify LFB of its desire to exercise the right of first negotiation set forth in this Section 2(a) with respect to the relevant ROFN Product. If rEVO timely provides
such notice to LFB, the Parties will negotiate in good faith for a period of up to [***] after LFB’s initial notice to rEVO regarding such rights towards an agreement pursuant to which rEVO would distribute such ROFN Product for all indications
in such country. If the Parties are unable to reach agreement during such [***] period, such right of first negotiation may be extended by the Parties or such right of first negotiation shall lapse and shall be of no further force or effect with
respect to the ROFN Product and indications identified in LFB’s notice to rEVO. For avoidance of doubt, LFB may distribute ROFN Products through one or more of its Affiliates and such activity shall not trigger the ROFN described in this
Section 2. 
 3. CONFIDENTIALITY 

(a) Confidential Information. All information that is disclosed or provided by one party (the “Disclosing Party”) to
the other party (the “Recipient”) pursuant to this Agreement, whether in oral, written, graphic, electronic, or any other form, shall be the “Confidential Information” of the Disclosing Party. Except to the extent
expressly authorized by this Agreement or by the other party in writing, during the term of this Agreement and for five (5) years thereafter, each party shall maintain in strict trust and confidence and shall not disclose to any third party or
use for any purpose other than as provided for in this Agreement any Confidential Information of the other party. Each party may use the other party’s Confidential Information only in connection with the exercise of rights granted to such party
hereunder, and for no other purpose. Each party agrees that it shall not use the other party’s Confidential Information for any purpose or in any manner that would constitute a violation of applicable laws. 

(b) Exceptions. The obligations of confidentiality and nonuse set forth in Section 3.1(a) shall not apply to any specific portion
of information that the Recipient can demonstrate by competent written proof: (a) is in the public domain or comes into the public domain through no fault of the Recipient; (b) is furnished to the Recipient by a third party rightfully in
possession of such information and not subject to a duty of confidentiality with respect thereto; (c) is already known by the Recipient at the time of receiving such Confidential Information from the Disclosing Party as evidenced by the
Recipient’s prior written records; or (d) is independently developed by the Recipient without access to the Disclosing Party’s Confidential Information. 

(c) Authorized Disclosure. Notwithstanding the foregoing in this Section 3, the Recipient may disclose certain Confidential
Information of the Disclosing Party to the extent such disclosure is required by law or regulation, or pursuant to a valid order of a court or other governmental body having jurisdiction; provided that the Recipient provides the Disclosing Party
with reasonable prior written notice of such disclosure and reasonable assistance in obtaining a protective order or confidential treatment preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used
only for the purposes for which the law or regulation required, or for which the order was issued. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 3
 
  

 (d) Return of Confidential Information. Upon termination or expiration of the
Agreement, or upon written request of the Disclosing Party, the Recipient shall promptly return to the Disclosing Party or destroy all documents, notes and other tangible materials representing the Disclosing Party’s Confidential Information
and all copies thereof; provided, however, that each party may retain (i) a single archival copy of the other party’s Confidential Information for the sole purpose of facilitating compliance with the surviving provisions of this Agreement
and (ii) computer generated back-up copies that are difficult to locate. 
 (e) Injunctive Relief. The parties expressly
acknowledge and agree that any breach or threatened breach of this Section 3 may cause immediate and irreparable harm to the non-breaching party that may not be adequately compensated by damages. Each party therefore agrees that in the event of
such breach or threatened breach and in addition to any remedies available at law, the non-breaching party shall have the right to secure equitable and injunctive relief, without the necessity of securing bond, in connection with such a breach or
threatened breach. 
 4. TERM 

(a) Term. 
 (i) This
Agreement shall become effective on the date hereof and shall continue in effect for twenty five (25) years thereafter unless sooner terminated in accordance with the provisions of this Agreement (the “Expiration Date”).
Additionally, this Agreement may be renewed or extended by mutual written agreement of rEVO and LFB. 
 (ii) This Agreement shall terminate
upon the following terms and conditions: 
 (A) Mutual Termination. This Agreement may be terminated upon the mutual agreement of
rEVO and LFB; 
 (B) Defaults. If either party defaults or otherwise materially breaches any provisions of this Agreement, and fails
to cure such default or breach within [***] after a written demand for performance by the other party, the non-defaulting party, in addition to any other rights it may have under applicable law, may, at its option, terminate this Agreement by giving
written notice thereof to the defaulting party which shall specify the effective date of termination; or 
 (C) Insolvency. If a
petition under any bankruptcy or insolvency law is filed by or against a party, or if either party suspends business or commits any act amounting to a business failure, the other party may, at its option, terminate this Agreement by giving written
notice thereof to the insolvent party which shall specify the effective date of termination. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 4
 
  

 (b) Effects of Termination; Survival of Certain Obligations. In the event of a
termination or expiration of this Agreement in accordance with the terms hereof, this Agreement shall immediately become null and void and have no effect, except that Section 3, this Section 4(b) and all other obligations of the parties
specifically intended to be performed after the termination of this Agreement shall survive any termination of this Agreement. All obligations of rEVO and LFB under this Agreement that arose prior to its termination or expiration and that have not
been fully performed in accordance with the terms of this Agreement prior to such termination or expiration shall survive any such termination or expiration of this Agreement. 

5. MISCELLANEOUS 

(a) Complete Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both
written and oral, among the parties hereto, or any of them, with respect to the subject matter hereof. 
 (b) Counterparts. This
Agreement may be executed in counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties, it being understood that all parties need not sign the same
counterpart. 
 (c) Notices. All notices, requests, claims, demands and other communications under this Agreement will be in writing
and will be deemed given if delivered personally, sent by overnight courier (providing written proof of delivery) or via facsimile (providing written proof of transmission), in each case with a copy (which shall not constitute notice) via electronic
mail to the parties at their e-mail address (if available): 
 If to LFB: 

Laboratoire français du Fractionnement 

et des Biotechnologies 
 3
avenue des Tropiques 
 ZA de Courtaboeuf, 91940 

Attention: General Counsel 

Fax: + 33 1 70 99 40 63 

E-mail: bergerm@lfb.fr 
 If
to rEVO Biologics, Inc. 
 rEVO Biologics, Inc. 

175 Crossing Blvd. 
 Framingham,
MA 01702 
 Attention: President 

Fax: 508-370-3797 
 E-mail:
yann.echelard@revobiologics.com 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 5
 
  

 (d) Amendments; Waivers. The parties may mutually amend or waive any provision of this
Agreement at any time. No amendment or waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by each of the parties. No waiver by any party of any default, misrepresentation or breach of warranty or
covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent
such occurrence. 
 (e) Assignment; Reliance of Other Parties. Neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned by any of the parties hereto in whole or in part (whether by operation of law or otherwise) without the prior written consent of the other parties and any attempt to make any such assignment without such consent shall be
null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties and their respective successors and assigns. This Agreement (including the documents and instruments
referred to herein) is not intended to confer upon any person or entity other than the parties hereto any rights or remedies under or by reason of this Agreement. 

(f) Interpretation. 
 (i)
Titles and headings to sections herein are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof. 

(ii) The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent
or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 (iii) The appendices hereto shall be construed with and as an integral part of this Agreement to the same extent as if the same had been
set forth verbatim herein. 
 (iv) In the event of any inconsistency between this Agreement and any appendix hereto, the appendix shall
prevail. 
 (g) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware
without regard to any rules of conflict of laws that would require the application of the laws of any other jurisdiction. 
 (h) Dispute
Resolution. 
 (i) In the event of any dispute, controversy or claim among the parties, or any of them, arising out of or
relating to this Agreement or matter related hereto, or the breach or invalidity thereof (collectively, a “Dispute”), the parties shall attempt in the first instance to resolve such Dispute through consultation among the executive
officers of the parties having requisite authority. The parties agree to attempt to resolve all Disputes arising hereunder promptly, equitably and in a good faith manner. The parties further agree to provide each other with reasonable access during
normal business hours to any and all non-privileged records, information and data pertaining to such Dispute, upon reasonable advance notice. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 6
 
  

 (ii) If the parties are unable to resolve the Dispute amicably within thirty
(30) days after giving notice of the dispute to the other party’s executive officer having requisite authority, the parties hereby (i) irrevocably and unconditionally submit to the jurisdiction of the state courts of Massachusetts and
to the jurisdiction of the United States District Court located in Boston, Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (ii) agree not to commence any suit, action or other
proceeding arising out of or based upon this Agreement except in the state courts of Massachusetts or the United States District Court located in Boston, Massachusetts, (iii) waive, and agree not to assert, by way of motion, as a defense, or
otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is
brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court and (iv) agree that the process may be served in the
manner provided in above for giving notices, or otherwise as permitted by statute of rule of court. 
 (iii) WAIVER OF JURY
TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT.

 (iv) Notwithstanding the foregoing of this Section, either party shall have the right, without waiving any right or remedy
available to such party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such party. 

(j) Force Majeure. No party shall bear any responsibility or liability for any damages arising out of any delay, inability to perform
or interruption of its performance of its obligations under this Agreement due to any acts or omissions of the other party hereto or for events beyond its reasonable control including, without limitation, acts of God, acts of governmental
authorities, acts of terrorism, acts of a public enemy, acts of civil or military authority including governmental priorities, or due to war, riot, fire, flood, civil commotion, insurrection, lack of or shortage of electrical power, or any other
cause beyond the reasonable control of such party. 
 (k) Severability. In the event that any one or more provisions of this
Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, by any court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and the parties
shall use their reasonable best efforts to substitute a valid, legal and enforceable provision which, insofar as practicable, implements the original purposes and intents of this Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  Page
 7
 
  

 (l) Relationship of Parties. Nothing in this Agreement is intended or should be
construed to create a partnership, joint venture, or employer-employee relationship between rEVO and LFB or any of their respective employees or agents. 

[Remainder of Page Intentionally Left Blank.] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed the day and year
first above written. 
  

			
	Laboratoire français du Fractionnement et des Biotechnologies
		
	By:	 	 /s/ Christian Bechon

	Name:	 	Christian Bechon
	Title:	 	CEO
	
	rEVO Biologics, Inc.
		
	By:	 	 /s/ Yann Echelard

	Name:	 	Yann Echelard
	Title:	 	President

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT
TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.EX-10.5

 Exhibit 10.5 

USE AND OCCUPANCY AGREEMENT 

This Use and Occupancy Agreement (“Agreement”) is entered into this 31st day of March, 2014, by and LFB USA, INC. (“LFB”)
and REVO BIOLOGICS, INC. with an address of 175 Crossing Boulevard, Framingham, Massachusetts (“Revo”). 
 WHEREAS, Revo (f/k/a
GTC Biotherapeutics Inc.), as tenant, and NDNE 9/90 Corporate Center, LLC ( “Landlord”) entered into that certain Amended and Restated Lease Agreement dated September 28, 2010 (the “Lease”) of certain premises comprised of
28,219 rentable square feet of space (the “Premises”), with approximately 8,331 rentable square feet being located on the fourth (4th) floor (the “Fourth Floor Premises”),
in the building known as 175 Crossing Boulevard, Framingham, Massachusetts (the “Building”); 
 WHEREAS, Revo has assigned the
Lease to LFB with Landlord’s consent; 
 WHEREAS, Revo and LFB have agreed, notwithstanding the assignment, that Revo can continue to
use and occupy portions of the Fourth Floor Premises located on the fourth (4th) floor, consisting of approximately 2,583 rentable square feet of space, and designated on the plan attached
hereto as Exhibit A, together with certain rights appurtenant thereto, as more particularly described herein (collectively, the “Occupancy Area”); and 

WHEREAS, Revo has agreed to use and occupy the Occupancy Area in accordance with this Agreement. 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, LFB and Revo, each
with intent to be legally bound, agree to the following: 
 1. CAPITALIZED TERMS Any capitalized terms not otherwise defined
in this Sublease shall have the meanings ascribed thereto in the Lease. 
 2. USE AND OCCUPANCY 

LFB agrees that, commencing as of March 31, 2014 (the “Occupancy Commencement Date”), and continuing until the Termination Date
(as defined below), Revo may use and occupy the Occupancy Area on the terms and conditions contained in this Agreement, in its present “AS IS” condition on the date hereof. LFB has made no representations, warranties or undertakings as to
the present or future condition of the Occupancy Area or the fitness and availability of the Occupancy Area for any particular use. The acceptance of the Occupancy Area by Revo shall constitute an acknowledgment by Revo that the Occupancy Area is in
the condition it is required to be in by this Agreement. 
 3. TERM 

The term of this Agreement shall commence on the Occupancy Commencement Date and, subject to the provisions set forth herein, shall continue
until the Lease expires, as may be extended by the terms of the Lease, unless terminated by Revo upon (30) days’ prior written notice given to the LFB (said date, the “Termination Date. 

 4. RENT 

Commencing on the Occupancy Commencement Date until the Termination Date, Revo shall pay occupancy charges (“Rent”) to LFB in the
amounts set forth below together with any other amounts due from Revo to LFB pursuant to this Agreement (“Additional Rent”): 
  

									
	 RENTAL PERIOD
	  	ANNUAL RENT	 	  	MONTHLY PAYMENT	 
	 March 31, 2014 – September 30, 2014
	  	$	58,763.25	  	  	$	4,896.94	  
	 October 1, 2015 – September 30, 2015
	  	$	60,700.50	  	  	$	5,058.34	  

 Each Monthly Payment (as described above) of the applicable Annual Rent shall be paid to LFB in advance on the first
(1st) day of each calendar month during the Term of this Agreement. If the term of this Agreement should expire other than on the last day of a month, any Monthly Payment of Rent and, if applicable, Additional Rent, paid by Revo and allocable
to such partial month shall be equitably apportioned. 
 5. OPERATING EXPENSES; REAL ESTATE TAXES; UTILITIES; SHARED SERVICES
AGREEMENT. 
 During the Term of this Agreement, Revo shall pay to LFB thirty-one percent (31%) of all charges arising in
connection with the Fourth Floor Premises, and nine and 15/100 percent (9.15%) of all other charges arising in connection with the Lease, including but not limited to: (i) the Real Estate Tax Escalations payable by LFB under
Section 6.1 of the Lease, (ii) the Operating Cost Escalations payable by LFB under Section 5.1 of the Lease, (iii) Park Expenses payable by LFB under Section 5.3 of the Lease; (iv) any utility charges incurred by LFB
with respect to the Premises; (v) any cost of expenses arising pursuant to the Services and Access Agreement attached as Exhibit K to the Lease for which LFB is responsible; and (vi) any other charge arising under the Lease for which LFB
is responsible. Such amounts shall be payable in equal monthly installments, in advance, subject to and in accordance with the terms and conditions of Sections 5.1, 5.3, 6.1, 8.3 and 8.4 of the Lease, which terms and conditions are incorporated
herein by reference and made a part hereof. 
 6. USE OF THE OCCUPANCY AREA  

(a) Revo may use and occupy the Occupancy Area as contemplated hereby solely for general office purposes, laboratory, research and
development, and light manufacturing uses consistent with the terms of the Lease and for no other purpose. Revo shall at no time permit more than persons to use and occupy the Occupancy Area than is permitted under the Lease or by any certificate of
occupancy then in effect for the Building. 
 (b) The “common area” corridors, stairs, and entryways providing direct access to
the Occupancy Area, as well as restrooms and common lobbies on the floor of the Building on which the Occupancy Area is located and the lounge, dining areas, reception areas, conference room and other areas within the Premises designated by LFB from
time to time for the common use of all occupants of the Premises, shall constitute the “Common Areas.” Revo shall be entitled 

  
 2 

 
to reasonable use and occupancy of the Common Areas in order to have access to the Occupancy Area, and to use the bathrooms on the floor of the Building on which the Occupancy Area is located and
to conduct its business within the Premises. 
 (c) Revo shall be responsible for any violations of all Federal, state and local laws,
ordinances, rules and regulations and the requirements of any Board of Fire Insurance Underwriters arising by virtue of Revo’s manner of use of the Occupancy Area. 

(d) Revo shall keep the Occupancy Area in good order and condition subject to reasonable wear and tear and, at the Termination Date, shall
remove all of Revo’s personal property and surrender the Occupancy Area in the condition required hereunder. Any damage caused to the Occupancy Area by such removal shall be repaired by Revo in a good and workmanlike manner, at Revo’s sole
cost and expense. 
 (e) Revo shall be responsible for any repair or maintenance of the Occupancy Area which is the consequence of
Revo’s act or omission. If LFB shall perform alterations to any portion of the Premises, LFB shall exercise reasonable efforts, to minimize any interference with Revo’s use of the Occupancy Area. LFB shall provide Revo with prior notice,
to be given at least three (3) business days before any work commences, that LFB intends to perform work to the Premises over a period of more than one (1) day that may cause undue noise (e.g., hammering, circular saws, demolition,
installation of pipes, etc.) and LFB shall use commercially reasonable efforts to schedule such work in such manner as will minimize unreasonable interference with the business or operations of Revo. 

(f) Revo acknowledges and agrees that its occupancy of the Occupancy Area is on a non-exclusive basis, and that LFB may grant additional
rights to use the Premises to such other parties as LFB may desire, with Revo’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed provided that such additional occupancy rights do not materially
adversely affect Revo’s use of the Occupancy Area. 
 (g) Revo acknowledges and agrees that its use and occupancy of the Occupancy
Areas shall be at all times subject to LFB’s reasonable rules and regulations, including without limitation, confidentiality and security requirements. Revo shall execute any and all documentation necessary to implement the foregoing
requirements. 
 7. EXTRA UTILITIES AND SERVICES 

(a) To the extent that the Landlord (or any party with an interest senior to that of Landlord) charges LFB for any additional service provided
to the Occupancy Area beyond that required to be supplied by the Lease (i.e. additional cleaning, after hours “HVAC,” etc.), Revo shall be responsible therefor to the extent Revo is responsible for such additional service being furnished.

 (b) LFB shall provide to Revo, at no additional cost to Revo, the following services: (i) High-speed internet; (ii) VoIP
telephony; (iii) wireless network connectivity; (iv) access to meeting rooms, on space available basis; (v) access to pantry/lunchroom in the Premises; (vi) staffed reception desk ; (vii) Revo’s name on the fourth (4th) floor lobby sign and suite sign; (viii) bulk mail service, excluding postage; (ix) copy services; (x) access to a boardroom with video conferencing capability; and (xi) the
furniture located in the Occupancy Area on the Occupancy Commencement Date; and (xii) janitorial and cleaning service to the extent such services are provided by Landlord pursuant to Lease. 

  
 3 

 (c) LFB shall provide to Revo the following services, upon request by Revo and at Revo’s
sole cost and expense, as “Additional Rent”: (i) audio and web conferencing; (ii) catering; (iii) infrastructure services – file storage, backup and recovery, VPN; (iv) IT support; and (v) additional furniture
or office equipment to the extent that they are not located in the Occupancy Area on the Occupancy Commencement Date. 
 8.
SIGNAGE 
 Revo shall have the right, with Landlord’s prior written consent if required under the Lease, to install its
standard signage in the Lobby Directory and at the entrance of the fourth (4th) floor suite in accordance with the terms of Section 8.6 of the Lease. 

9. ALTERATIONS 

Revo shall not make any alterations, improvements or installations in or to the Occupancy Area without the prior written consent of LFB, which
consent shall not be unreasonably withheld. Any permitted alterations and improvements shall be subject to the terms and conditions of the Lease, and in those instances where applicable, shall be subject to the Landlord’s approval as provided
in the Lease. 
 10. ASSIGNMENT AND SUBLETTING 

Revo shall not assign this Agreement or sublet the Occupancy Area without the prior written consent of LFB, which may be withheld in
LFB’s sole and absolute discretion. 
 11. INSURANCE 

Revo, at its sole cost and expense, shall, throughout the term of this Agreement, procure, keep in force and pay for a policy of general
liability and property damage insurance at least as comprehensive in coverage terms as is carried by the LFB pursuant to the Lease, and under which LFB and Landlord are indemnified against all claims and demands for bodily injury to or death of
persons or damage to property which may be claimed to have arisen out of the use of the Occupancy Area by Revo or its partners, employees, agents, independent contractors or invitees. Revo’s liability insurance policies shall have such other
characteristics as are required under the Lease and Revo shall provide evidence of such insurance reasonably satisfactory to LFB and Landlord on or before the Commencement Date. 

12. INDEMNITY 

Revo agrees to indemnify and save harmless LFB and Landlord and each of their respective partners, employees, agents, independent contractors,
clients and invitees each an “Indemnified Party” and collectively, the “Indemnified Parties”), from and against any and all claims, liabilities, suits, judgments, awards, damages, losses, fines, penalties, costs and expenses,
including without limitation reasonable attorneys’ fees, that any Indemnified Party may suffer, incur or be liable for by reason of or arising out of the breach by Revo or Revo’s employees, agents, independent contractors or invitees of
any of the duties, obligations, liabilities or covenants applicable hereunder or relating to its occupancy or use of the Premises. Revo shall promptly notify LFB of any such claim and shall promptly deliver to the other a copy of any summons or
other process, pleading or notice issued in any action or proceeding to assert any such claim. Revo shall, upon the written request of any Indemnified Party, defend any such action or proceeding at its own cost and expense. 

  
 4 

 13. OCCUPANT’S OBLIGATIONS UPON TERMINATION OF THIS AGREEMENT 

Revo agrees that it will keep the Occupancy Area in substantially the same condition as received on the Commencement Date, and will, at the
Termination Date or other termination of the term of this Agreement, surrender and deliver up the same in like condition, ordinary wear and tear and damage by the elements, condemnation, fire, and other casualty excepted. Failure to so timely
surrender the Occupancy Area, time being of the essence, shall render Revo an occupant at sufferance, and Revo shall be liable for use and occupancy charges equal to two times the rate of Rent payable under Paragraph 4 hereof. 

14. BROKERS 
 LFB
and Revo represent to each other that no broker was used in connection with the execution of this Agreement. Each party agrees to indemnify and hold the other harmless from any and all claims of any other broker claiming to have dealt with such
party. 
 15. DEFAULTS 

Each of the following shall be a default of Revo: 

(a) Revo fails to make any payment of Rent, or any Additional Rent or any other payment Revo is required to make when such payment is due and
such failure shall continue for five (5) business days after written notice from LFB to Revo (“Monetary Default”). 
 (b)
Except as provided in clause (c) below, Revo fails to perform any obligation of Revo pursuant to this Agreement other than a Monetary Default, and that failure continues for fifteen (15) business days after written notice from LFB. 

(c) Revo fails to timely surrender the Occupancy Area pursuant to Paragraph 13 hereof, in which case the terms and conditions of said
Paragraph 13 shall apply, and LFB shall additionally have the remedies described in Paragraph 16 below. 
 16. REMEDIES 

(a) In the event of a default by Revo, LFB shall have the power and right: 

(i) To enforce any remedies generally available at law or in equity to a landlord upon a default by tenant; 

(ii) To obtain injunctive relief against any continuing default by Revo; 

(iii) To maintain this Agreement in effect and collect the Rent, Additional Rent and any other payments due from Revo to LFB;

 (iv) To exercise LFB’s rights under Paragraph 13 in the case of any holding over by Revo; and 

(v) To terminate this Agreement and recover exclusive possession of the Occupancy Area. Revo nevertheless agrees to remain
liable for any and all damage, deficiency or loss of Rent and Additional Rent which LFB may sustain by reason of the exercise of such remedies. 

  
 5 

 (b) In the event of a compromise or settlement of any default, such compromise or settlement
shall not constitute a waiver of any breach or any covenant, condition or agreement herein contained, nor shall it operate as a waiver of the covenant, condition or agreement itself, or of any subsequent breach thereof. 

17. SUBORDINATION TO THE LEASE 

Revo acknowledges that a true and complete copy of the Lease has been provided to Revo and that this Agreement is subject and subordinate to
the Lease. Revo shall not, in its use and occupancy of the Occupancy Area, do or permit to be done any act in or related to the Occupancy Area which constitutes a default under the terms of the Lease. 

18. FIRE, CASUALTY AND EMINENT DOMAIN 

In the event of a fire, casualty or taking that affects the Premises but that does not result in termination of the Lease, the Rent hereunder
shall be abated in the direct proportion which the rent payable by LFB under the Lease and allocable to the Occupancy Area is abated. The provisions of this Paragraph 18 shall be considered an express agreement governing any cause of damage or
destruction to the Occupancy Area by fire or other casualty, and no local or state statute, law, rule or regulation, now or hereafter in effect, providing for such a contingency shall have any application in such case, to the extent permitted by
law. 
 19. SEVERABILITY AND GOVERNING LAW 

This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts. If any provision hereof or
the application hereof to any person or circumstance shall to any extent be invalid or unenforceable, the remaining provisions hereof, or the application of such provision to the person or circumstances other than those as to which it is invalid or
unenforceable, shall not be affected thereby, and each provision hereof shall be valid and enforceable to the extent permitted by law. 

20. NOTICES 
 Any
notice, statement, certificate, consent, approval, disapproval, request or demand required or permitted to be given in this Agreement shall be in writing delivered by hand with a copy sent by United States mail, registered or certified, postage
prepaid, as the case may be: 
 To LFB at the Premises/ following address: 

175 Crossing Blvd. 
 Framingham,
MA 01702 
 Attention: William Gavin, President 

Telephone: (508)-370-5100 

E-mail: William.gavin@lfb-usa.com 

  
 6 

 and to Revo at the Occupancy Area/ the following address: 

rEVO Biologics, Inc. 
 175
Crossing Blvd. 
 Framingham, MA 01702 

Attention: Yann Echelard, President 

Fax: (508) 370-3797 
 E-mail:
yann.echelard@revobiologics.com 
 Either party by notice to the other may change or add persons and places where notices are to be sent or
delivered. In no event shall notice have to be sent on behalf of either party to more than two (2) persons. Notices will be deemed served when received by hand or delivery by reputable overnight courier providing receipt of delivery, at such
time as such delivery is received or refused. 
 21. SERVICES, NO REAL ESTATE INTEREST. 

Except as otherwise expressly set forth in this Agreement, LFB shall not be obligated to deliver any services to Revo in connection with its
use of the Occupancy Area. This Agreement grants non-exclusive rights of use and occupancy only. No interest in real estate is granted. 

22. ENTIRE AGREEMENT 

This Agreement contains the entire agreement between LFB and Revo and can be changed only by an amendment executed by both LFB and Revo. 

23. NOTICE OF AGREEMENT 

LFB and Revo agree that neither party shall record this Agreement, nor shall Revo have any right to record a notice of this Agreement. 

24. BINDING EFFECT 

The submission of this Agreement for examination and negotiation does not constitute an offer to sublease or a reservation of, or an option
for, the Occupancy Area. Once fully executed, all the covenants, agreements and undertakings in this Agreement contained shall extend to and be binding upon the legal representatives, successors and assigns of the respective parties hereto, the same
as if they were in every case named and expressed, but nothing herein shall be construed as a consent by LFB to any assignment or subletting by Revo of any interest of Revo in this Agreement. 

25. COUNTERPARTS 

This Agreement may be executed in one or more counterparts, each of which shall constitute an original and all of which shall constitute but
one agreement. 
 [The remainder of this page is intentionally left blank.] 

  
 7 

 IN WITNESS WHEREOF, LFB and Revo have each caused these presents to be executed as a sealed
instrument as of the day and year first above written. 
  

			
	LFB USA, INC.,
	a Delaware corporation
		
	By:	 	 /s/ William Gavin

	Name:	 	William Gavin
	Title:	 	President
	
	 REVO BIOLOGICS, INC.,
 a
Massachusetts corporation

		
	By:	 	 /s/ Yann Echelard

	Name:	 	Yann Echelard
	Title:	 	President

  

  
 8 

 EXHIBIT A 

Occupancy Area 
  

 

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]